Semaglutide Weekly Injection Active Ingredient in Ozempic and Wegovy 15% Body Weight Reduction GLP-1 Receptor Agonist FDA Approved for Type 2 Diabetes (2017) and Weight Loss (2021) Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain Tirzepatide Weekly Injection Active Ingredient in Mounjaro 20% Body Weight reduction Dual GLP-1 and GIP Receptor Agonist FDA Approved for Type 2 Diabetes (2022) and on Fast-track for Weight Loss Approval in 2023 Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain These injections are GLP-1 medications that have been FDA-approved for Type 2 diabetes because of their ability to lower blood sugar and raise insulin levels
Compared with traditional peptide APIs, GLP-1 programs introduce several new operational pressures
Why U100 Syringes Are the Standard Today In most countries, U100 insulin is the standard strength used for both human and analog insulin types
Cc sn phm t sa c cha protein beta-casein c kh nng lm tng nng Glutathione trong c th
Energy dips are most pronounced in the first 13 weeks of treatment or during dose escalations
Audit the language across your whole menu now, while the enforcement wave is still concentrated on GLP-1s, rather than after it reaches the compound you rely on most